Josép María Ribera Santasusana-rekin lankidetzan egindako argitalpenak (15)

2022

  1. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

    Histopathology, Vol. 81, Núm. 6, pp. 826-840

2021

  1. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

    Leukemia, Vol. 35, Núm. 12, pp. 3585-3588

2019

  1. Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma

    Leukemia and Lymphoma

2017

  1. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome

    Hematological Oncology, Vol. 35, Núm. 4, pp. 520-527

2012

  1. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/ Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Haematologica, Vol. 97, Núm. 2, pp. 310-317

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Unrelated Transplantation for Poor-Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Outcome Analysis and Study of the Impact of Hematopoietic Graft Source

    Biology of Blood and Marrow Transplantation, Vol. 16, Núm. 7, pp. 957-966

2009

  1. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study

    Haematologica, Vol. 94, Núm. 9, pp. 1282-1288

2008

  1. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival

    Journal of Clinical Oncology, Vol. 26, Núm. 4, pp. 577-584

2007

  1. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: Impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes

    British Journal of Haematology, Vol. 139, Núm. 1, pp. 70-80

  2. Sirolimus as Part of Immunosuppressive Therapy for Refractory Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 13, Núm. 6, pp. 701-706

2006

  1. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: Influence of stem cell source [13]

    Leukemia

  2. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 2, pp. 172-183

2005

  1. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-)

    Clinical Cancer Research, Vol. 11, Núm. 21, pp. 7757-7763

2002

  1. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx®), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study

    Haematologica, Vol. 87, Núm. 8, pp. 822-827